You searched for side effects - Page 37 of 311

Evaluating the effectiveness and safety of ixazomib-dexamethasone versus pomalidomide-dexamethasone combination for the treatment of patients with relapsed or refractory multiple myeloma.

$Evaluating the effectiveness and safety of ixazomib-dexamethasone versus pomalidomide-dexamethasone combination for the treatment of patients with relapsed or refractory multiple myeloma.$

Posted by Medivizor on Apr 29, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro)-dexamethasone (Decadron) (ixa-dex) versus pomalidomide (Pomalyst)-dexamethasone (pom-dex) combination for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that ixa-dex was safe and as effective as pom-dex...

Comparing the effectiveness and safety of avanafil and sildenafil for the treatment of patients with erectile dysfunction.

Posted by Medivizor on Apr 26, 2022 in Erectile dysfunction | 0 comments

In a nutshell This study compared the effectiveness and safety of avanafil (Stendra) with sildenafil (Viagra) for the treatment of patients with erectile dysfunction (ED). The data showed that avanafil had higher effectiveness compared to sildenafil in improving the symptoms of ED after 12 weeks. Some background Erectile dysfunction...

Comparing the effectiveness and safety between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.

Posted by Medivizor on Apr 26, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness and safety of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and modified non-Hodgkin lymphoma (NHL) Berlin-Frankfurt-Münster-90 (NHL-BFM-90; cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, methotrexate, vindesine, dexamethasone, cytarabine)...

Long-term safety and effectiveness of acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia

Posted by Medivizor on Apr 26, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) versus obinutuzumab with chlorambucil (Leukeran) in patients with chronic lymphocytic leukemia (CLL) that have never received treatment (treatment-naive). This study concluded that the...

Comparing the effectiveness and safety of trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in patients with high-risk HER2+ early breast cancer.

Posted by Medivizor on Apr 14, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of trastuzumab emtansine (T-DM1; Kadcyla) plus pertuzumab (Perjeta) versus taxanes plus trastuzumab (Herceptin) plus pertuzumab (THP) in patients with high-risk HER2-positive (+) early breast cancer (BC) after previous treatment with anthracycline-based chemotherapy. The data showed that...

Evaluating the effectiveness and safety of adding ixazomib to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma after ASCT.

Posted by Medivizor on Apr 10, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) maintenance therapy after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (MM). The data showed that the addition of ixazomib to lenalidomide maintenance improved survival without cancer...

Evaluating the effectiveness and safety of low-intensity extracorporeal shock wave therapy for patients with chronic pelvic pain syndrome and erectile dysfunction.

Posted by Medivizor on Apr 10, 2022 in Erectile dysfunction | 0 comments

In a nutshell This study evaluated the effectiveness and safety of low-intensity extracorporeal shock wave therapy (LSWT) for patients with chronic pelvic pain syndrome (CPPS) and erectile dysfunction (ED). The data showed that LSWT was safe and effective in improving the symptoms of these patients. Some background CPPS is lower abdominal pain usually...

Evaluating the long-term effectiveness of adding ribociclib to hormone therapy in younger patients with HR+/HER2- advanced breast cancer.

Posted by Medivizor on Apr 10, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness of adding ribociclib (Kisqali) to endocrine (hormone) therapy in pre-/perimenopausal patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding ribociclib to hormone therapy significantly improved survival outcomes than hormone...

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of a new hormonal therapy, SHR3680 (rezvilutamide), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that SHR680 was well tolerated and had promising effectiveness in these patients. Some background Metastatic...

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

$Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.$

Posted by Medivizor on Apr 3, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of mosunetuzumab (RG7828) for the treatment of patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL). The data showed that mosunetuzumab resulted in long-lasting complete responses with manageable side effects for these patients. Some background NHL is cancer that...

Comparing the effectiveness and safety of immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone for triple-negative breast cancer.

Posted by Medivizor on Apr 3, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of immune checkpoint inhibitors (ICI) plus chemotherapy versus chemotherapy alone for the treatment of patients with triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was more effective than chemotherapy alone and was associated with a higher rate of side...

Evaluating antibody response rates of patients with chronic lymphocytic leukemia to a third dose of mRNA COVID-19 vaccine

Posted by Medivizor on Mar 20, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the antibody response to a third mRNA COVID-19 vaccine of patients with chronic lymphocytic leukemia (CLL) who had failed to achieve an antibody response after the standard two-dose vaccination regimen. This study concluded that approximately a quarter of patients responded to the third...

Evaluating the effectiveness and safety of ixazomib-dexamethasone versus pomalidomide-dexamethasone combination for the treatment of patients with relapsed or refractory multiple myeloma.

Comparing the effectiveness and safety of avanafil and sildenafil for the treatment of patients with erectile dysfunction.

Comparing the effectiveness and safety between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.

Long-term safety and effectiveness of acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia

Comparing the effectiveness and safety of trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in patients with high-risk HER2+ early breast cancer.

Evaluating the effectiveness and safety of adding ixazomib to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma after ASCT.

Evaluating the effectiveness and safety of low-intensity extracorporeal shock wave therapy for patients with chronic pelvic pain syndrome and erectile dysfunction.

Evaluating the long-term effectiveness of adding ribociclib to hormone therapy in younger patients with HR+/HER2- advanced breast cancer.

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of mosunetuzumab for patients with relapsed/refractory non-Hodgkin lymphoma.

Comparing the effectiveness and safety of immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone for triple-negative breast cancer.

Evaluating antibody response rates of patients with chronic lymphocytic leukemia to a third dose of mRNA COVID-19 vaccine

Categories

Recent Posts

Archives

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email